ALLSCHWIL, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX:SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today provides a business update, including development programs’ progress and its efforts to secure funding for these projects.
Read more at globenewswire.comSpexis provides business update
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here